ImmunityBio, Inc. IBRX Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromShortTermDebt.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is ImmunityBio, Inc.'s debt issuance proceeds?
- ImmunityBio, Inc. (IBRX) reported debt issuance proceeds of $61K in Q1 2026.
- What does debt issuance proceeds mean?
- Cash received from taking on new debt.
- How do you interpret debt issuance proceeds?
- Higher inflows provide immediate liquidity but increase future interest obligations and leverage risk.
- How does debt issuance proceeds compare across companies?
- Used by companies to manage liquidity needs when equity financing is undesirable or unavailable.